Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis

Clinical Nephrology

Volumn 67, Issue 3, 2007, Pages 188-192

  Unbehaun, Rolf ^a   Lauerwald, W ^a  

^a Nephrologische Gemeinschaftspraxis   (Germany)

Author keywords

Calcimimetics; Chronic kidney disease; Cinacalcet HCl; Hyperparathyroidism; Parathyromatosis

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM PHOSPHATE; CINACALCET; CLOPIDOGREL; PARATHYROID HORMONE; SEVELAMER; VITAMIN D;

AGED; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; RECOMMENDED DRUG DOSE; REOPERATION; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33947288643     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP67188     Document Type: Article

References (24)

1. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69: 33-43.
2. Blacher J, Guerin AP, Pannier B, Marchais V, London GM. Arterial calcifications, arterial stifffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 939-942.
3. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525.
4. 2+-sensing receptor from bovine parathyroid. Nature. 1993; 366: 575-580.
5. Brown EM, Hebert SC. A cloned extracellular calcium-sensing receptor: molecular mediator to the actions of extracellular calcium on parathyroid and kidney cells. Kidney Int. 1996; 49: 1042-1046.
6. Cunningham J. Management of secondary hyperparathyroidism. Ther Apher Dial. 2005a; 9 (Suppl 1): 35-40.
7. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcintimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005b; 68: 1793-1800.
8. Daphnis E, Stylianou K, Katsipi I, Stratigis S, Karamitopoulou E, Karkavitsas N, Kyriazis J. Parathyromatosis and the challenge of treatment. Am J Kidney Dis. 2006; 48: 502-505.
9. Drüeke TB. Calcinumetics versus vitamin D: what are their relative roles? Blood Purif. 2004; 22: 38-43.
10. Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E. 1.25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol. 2004; 89/90: 507-511.
11. Fitko R, Roth SI, Hines JR, Roxe DM, Cahill E. Parathyromatosis in hyperparathyroidism. Hum Pathol. 1990; 21: 234-237.
12. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993; 92: 1436-1443.
13. Ghanesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.
14. Hoerl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004; 19 (Suppl 5): V2-8.
15. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995; 333: 166-174.
16. Maxwell PH, Winearls CG. Recurrence of autonomous hyperparathyroidism in dialysis patients. Nephrol Dial Transplant. 1997; 12: 2195-2200.
17. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005a; 20: 2186-2193.
18. Moe SM, Goodman WG, Cunningham J, Druecke T, Adler S, Rosansky SJ, Albizem MB, Olson KA, Addison J, Sprague SM. Cinacalcet HCl sustains long-term control of secondary hyperparathyroidism (HPT). Poster presented at Annual Meeting of the American Society for Neurochemistry. 2005b; (F-P0755).
19. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Kidney disease outcomes quality initiative. Am J Kidney Dis. 2003; 42 (Suppl 3): 51-5201.
20. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad USA. 1998; 95: 4040-4045.
21. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003; 14: 575-583.
22. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Ren Physiol. 2004; 288: 253-264.
23. Serra AL, Schwartz AA, Wick FH, Martz HP, Wuthneh RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1315-1319.
24. Stehman-Breen C, Muirhead N, Thorning D, Sherrard D. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis. 1996; 28: 502-507.